Median weekly platelet counts for various patient populations treated for CIT with romiplostim from a study of 173 patients with CIT. Solid tumor patients with no predictors of romiplostim nonresponse (n = 122, blue); solid tumor patients with predictors of romiplostim nonresponse (n = 31, gray) including bone marrow invasion by tumor, prior pelvic irradiation, or prior temozolomide treatment; patients with aggressive lymphoma (n = 13, red); and patients with myeloma (n = 7, purple). All patients with lymphoma and myeloma had known marrow involvement by tumor. PNR, predictors of nonresponse. Reproduced with permission from Al-Samkari et al.⁵